Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
The effect of autistic traits on response to and side-effects of pharmacological ADHD treatment in children with ADHD: results from a prospective clinical cohort
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk vetenskap, Barn- och ungdomspsykiatri. Child and Adolescent Psychiatric Clinic, Stockholm, Sweden.ORCID-id: 0000-0003-0789-6906
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk vetenskap, Barn- och ungdomspsykiatri. Child and Adolescent Psychiatric Clinic, Stockholm, Sweden.
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet, PO Box 281, SE171 77, Stockholm, Sweden; Stockholm Health Care Services, Region Stockholm, Sweden.
Visa övriga samt affilieringar
2022 (Engelska)Ingår i: Journal of Neurodevelopmental Disorders, ISSN 1866-1955, Vol. 14, nr 1, artikel-id 17Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

BACKGROUND: Attention deficit hyperactivity disorder (ADHD) is a common childhood behavioral condition that globally affects an average of around 5% of children and is associated with several adverse life outcomes. Comorbidity with autism spectrum disorder (ASD) is highly prevalent. Pharmacological treatment for ADHD symptoms has been shown to be effective. However, the prevailing perception is that children with ADHD and concomitant ASD symptoms report poorer efficacy and more side effects. This has been supported by studies on this population, but prospective studies directly comparing children with ADHD and different levels of ASD symptoms are lacking. We aimed to assess if children with ADHD and concomitant ASD symptoms differ regarding effects and side-effects of pharmacological ADHD treatment compared to children with ADHD without ASD traits. This is to our knowledge the second study to directly compare the effect of ADHD medication between ADHD patients with different levels of ASD symptoms.

METHODS: In a non-randomized, observational, prospective cohort study, 323 patients aged 6 to 17 years who were diagnosed with ADHD and starting pharmacological treatment were divided into two groups: one with high level of ASD symptoms (ASD group, N=71) and one with low level of ASD symptoms (non-ASD group, N = 252). Treatment outcome was measured as ADHD symptoms, and evaluated using the Swanson, Nolan and Pelham Teacher and Parent ADHD rating scale-version IV (SNAP-IV). Side-effects were evaluated using the Pediatric Side Effects Checklist (P-SEC), at 3 months follow-up.

RESULTS: From baseline to 3 months, there was no significant difference in neither treatment effect nor number of clinically significant adverse events experienced between the ASD group and the non-ASD group.

CONCLUSIONS: Our results did not implicate that ADHD patients with concomitant ASD symptoms have decreased treatment effect of ADHD medication than patients with ADHD without concomitant ASD symptoms. Neither did the results support that ADHD patients with ASD symptoms experienced significantly more side-effects than ADHD patients without ASD symptoms. Although, we did not analyze different medications separately, this is in line with the only previous study directly comparing methylphenidate treatment in children with or without ASD.

Ort, förlag, år, upplaga, sidor
BioMed Central, 2022. Vol. 14, nr 1, artikel-id 17
Nyckelord [en]
ADHD, Adverse event, ASD, Effect, Pharmacological treatment
Nationell ämneskategori
Psykiatri
Forskningsämne
psykiatri
Identifikatorer
URN: urn:nbn:se:umu:diva-193156DOI: 10.1186/s11689-022-09424-2ISI: 000765120300001PubMedID: 35249540Scopus ID: 2-s2.0-85125843011OAI: oai:DiVA.org:umu-193156DiVA, id: diva2:1645779
Tillgänglig från: 2022-03-18 Skapad: 2022-03-18 Senast uppdaterad: 2023-09-05Bibliografiskt granskad

Open Access i DiVA

fulltext(919 kB)118 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 919 kBChecksumma SHA-512
069d5627888123afcfa8ac0aad731a65ab4ce29434ed85e95bb05565a3b24462353bdbee91d6411f8f3ec6ef729a9b37a7567947c8ca344190a7eb625f27b440
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Lilja, MariaHalldner, Linda

Sök vidare i DiVA

Av författaren/redaktören
Lilja, MariaHalldner, Linda
Av organisationen
Barn- och ungdomspsykiatri
I samma tidskrift
Journal of Neurodevelopmental Disorders
Psykiatri

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 118 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 269 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf